index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
3,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,ras,protein,,hras,uniprot,p01112,plasma membrane,go:0005886,positive,i,upregulated signature,,,,,,['719'],nan,nan,acquired resistance to akt inhibition is associated with upregulated ras signature,pmc2911390,1,10,19,1,29
6,braf,protein,kinase,braf,uniprot,p15056,cytoplasm,go:0005737,egfr,protein,receptor,egfr,uniprot,p00533,cell membrane,go:0009986,negative,i,mutation,t790m,,lung cancer,lung,human,['1005'],nan,nan,"for example, recent clinical trial result showed that the response rate of non‐small‐cell lung cancer patients to vemurafenib (braf inhibitor) was 42% (hyman et al., 2015), suggesting that not every braf mutant non‐small‐cell lung cancer patients responded to braf‐targeted therapy; ras oncogene is still considered ‘undruggable’, with no effective ras inhibitors in clinical use; in egfr‐targeted therapy, although initial response rates are high (71.2–83%) among patients with egfr mutations, all patients eventually develop resistance (chong and janne, 2013). the most common mechanism of resistance to egfr inhibitors is a secondary mutation in egfr itself (t790m, threonine‐to‐methionine amino acid change at position 790), which renders the activated kinase insensitive to these agents (kobayashi et al., 2005; yu et al., 2013).",pmc5467491,1,10,19,1,29
25,brafv600e,protein,mutated,braf,uniprot,p15056,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,i,insensitivity,erk dependency,human thyroid carcinoma,carcinoma,thyroid,human,['237'],nan,nan,brafv600e-mutated human thyroid carcinoma cells are insensitive to relief of erk dependent upstream negative feedback.,pmc5599027,1,10,19,1,29
39,da-raf,protein,,,uniprot,q9y5s8,cytoplasm,go:0005737,ras,protein,,ras,uniprot,p01112,plasma membrane,go:0005886,negative,d,binds,cytoplasm,rle cells,epithelial,lung,mouse,['818'],nan,nan,"da-raf binds to active ras and suppresses the erk pathway. in consequence, intrinsic da-raf serves as a positive regulator of myogenic differentiation [28] and lung alveolarization [29], both of which are prevented by the ras—erk pathway. accordingly, we examined whether da-raf is required for tgf-β1-induced emt through suppressing the ras—erk pathway. a coimmunoprecipitation assay showed that stimulation of rle cells with tgf-β1 induced the binding of da-raf to ras (fig 5a). thus, we analyzed the phosphorylation status of mek1/2 and erk1/2 in the control and da-raf knockdown cells. endogenous da-raf as well as a-raf was expressed at a constant level for 60 min during tgf-β1 stimulation in the control cells (fig 5b). in these cells, the phosphorylation levels of both mek1/2 and erk1/2 were transiently elevated at around 5 min after tgf-β1 stimulation and then declined to basal levels by 15 min. on the other hand, their phosphorylation levels were higher in da-raf knockdown cells than in the control cells at every time point for at least 60 min (fig 5b). these results suggest that the binding of da-raf to ras, which is activated by tgf-β1 stimulation, interferes with the activation of mek and erk in rle cells.",pmc4440819,1,10,19,1,29
55,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,positive,i,pathway activation,,,,,human,['682'],nan,nan,"“to exclude that the tumors had acquired resistance during the in vivo drug treatment, we isolated the tumors to re-establish secondary organoids and subjected these to identical drug tests. […] indeed, in agreement with lower drug concentrations that proved to be ineffective in blocking proliferation in vitro (figure 1—figure supplement 1, video 1), we speculate that the in vivo drug concentrations were insufficient to effectively block the egfr-mek-erk pathway.”",pmc5127645,1,10,19,1,29
56,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,i,signaling,,,,lung,human,['1006'],nan,nan,"together, there is an urgent and unmet need for novel therapeutic approaches to effectively block egfr/ras/raf/mek/erk signaling. new insights into the regulation of mitogen‐activated protein kinase (mapk)/erk signaling pathway could reveal new therapeutic point of intervention, therefore are greatly needed. given that many lung adenocarcinomas lacking egfr/ras/raf mutations also displayed significant mapk activation (cancer genome atlas research, 2014), it is reasonable to predict that there are additional, still undetected mapk pathway regulators.",pmc5467491,1,10,19,1,29
63,egfr,protein,receptor,egfr,uniprot,p00533,cell membrane,go:0005886,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,i,inhibition,egfr-ras-erk pathway,,,,,['658'],nan,nan,robust inhibition of the egfr-ras-erk pathway sensitizes for navitoclax-induced cell death.,pmc5127645,1,10,19,1,29
92,il-1β,protein,interleukin,,uniprot,p01584,extracellular space,go:0005615,mapk,protein,,mapk,uniprot,p27361,cytoplasm,go:0005737,positive,i,activation,,primary cortical astrocyte,astrocyte,brain,,['943'],nan,nan,"the present study employs an interleukin-1β (il-1β) stimulated primary cortical astrocyte model in vitro and a nigrostriatal pathway injury model in vivo to mimic the astrocyte activation induced by traumatic brain injury. the activation of gfap, sirt1, and mapk pathways were detected by western blot; astrocyte morphological hypertrophy was assessed using immunofluorescence staining; in order to explore the neuroprotective effect of regulation sirt1 expression and mapk pathway activation, the motor and neurological function tests were assessed after injury.",pmc5372348,1,10,19,1,29
124,mek,protein,,map2k1,uniprot,q02750,cytoplasm,go:0005737,ras,protein,,hras,uniprot,p01112,plasma membrane,go:0005886,negative,i,downregulation,,lung cancer cell lines,,lung,human,['734'],nan,nan,"downregulation of the ras signature by mek inhibition: lung cancer cell lines were grown in standard media. vehicle (dmso) or pd325901 (0.1 μm) was added to cells for 6 or 24 hours. rna was extracted, and gene expression profiling was performed on affymetrix arrays as described below. data from each post-dose group was normalized to the cell line-matched vehicle control.",pmc2911390,1,10,19,1,29
134,mek,protein,,,uniprot,q02750,cytoplasm,go:0005737,vegf,protein,cytokine,vegfa,uniprot,p15692,extracellular region,go:0005576,negative,d,inhibition,,a375 melanoma,melanoma,skin,human,['535'],nan,nan,"sumimoto et al. demonstrated that brafv600e mutant cell lines can produce immunosuppressive cytokines such as vegf, il-6, and il-10 and that mek inhibition with u0126 and braf inhibition using brafv600e specific rnai suppressed secretion of these cytokines. il-12 and tnf-α production by dcs exposed to supernatant from the braf mutant a375 melanoma cell line prior to maturation by lps was suppressed (36). this inhibitory effect was mediated by il-6, il-10, and vegf and could be partially reversed by pre-treatment of the melanoma cells with brafv600e specific rnai, indicating that constitutive activation of the mapk pathway in melanoma cells may lead to compromised dc function and that this immune evasion may be overcome by mapk inhibition. in a separate study, il-10 expression in the melanoma line a375 was found to be induced by tgf-β, an effect that was mediated by cross-talk between the smad, pi3k/akt, and mapk pathways (37).",pmc3809567,1,10,19,1,29
162,p38 mapk,protein,,,uniprot,p53778,cytoplasm,go:0005737,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,negative,i,inhibition,,nes2y,pancreatic β-cells,pancreas,human,['461'],nan,nan,"there are data supporting the idea that the p38 mapk signaling pathway could be involved in apoptosis induction by fas in pancreatic β-cells [10,18]. in the present study, we demonstrated that p38 mapk is activated during apoptosis induction by stearic acid (sa) in the human pancreatic β-cells nes2y. therefore, we tested the role of p38 mapk signaling pathway activation in apoptosis induction by sa, representing saturated fas, in nes2y cells. crosstalk between p38 mapk pathway activation and erk pathway inhibition, after sa application, was also tested. we demonstrated that the activation of the p38 mapk pathway could be somehow involved in apoptosis induction by sa in the human pancreatic β-cells nes2y. however, this involvement does not seem to play a key role. crosstalk between p38 mapk pathway activation and erk pathway inhibition in nes2y cells seems likely. thus, the erk pathway inhibition by p38 mapk activation does not also seem to be essential for sa-induced apoptosis.",pmc4783893,1,10,19,1,29
203,ras,protein,,hras,uniprot,p01112,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,positive,i,inhibition,erk phosphorylation,,,blood,human,['1002'],nan,nan,"in conclusion, we showed that the ras-braf-mapk-erk pathway is one of the cellular processes affected in cll and identified novel cll drivers. patients with mutations in genes of the ras-braf-mapk-erk pathway had adverse biological features and most of them required treatment. furthermore, our results suggest that inhibition of erk phosphorylation in this subgroup of mutated cll patients can be achieved using new, specific erk inhibitors that have recently entered clinical trials. pharmacological inhibition of the ras-braf-mapk-erk pathway may represent a therapeutic approach to improve responses in this subgroup of cll patients.",pmc6395334,1,10,19,1,29
237,src,protein,non-receptor tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,rps6,protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,negative,i,phosphorylation,,,thyroid,,human,['861'],nan,nan,"advanced stages of papillary and anaplastic thyroid cancer continue to be plagued by a dismal prognosis, which is a result of limited effective therapies for these cancers. due to the high proportion of thyroid cancers harboring mutations in the mapk pathway, the mapk pathway has become a focal point for therapeutic intervention in thyroid cancer. unfortunately, unlike melanoma, a similar responsiveness to mapk pathway inhibition has yet to be observed in thyroid cancer patients. to address this issue, we have focused on targeting the non-receptor tyrosine kinase, src, and we and others have demonstrated that targeting src results in inhibition of growth, invasion, and migration both in vitro and in vivo, which can be enhanced through the combined inhibition of src and the mapk pathway. therefore, we examined the efficacy of the combination therapy across a panel of thyroid cancer cell lines representing common oncogenic drivers (braf, ras, and pik3ca). interestingly, combined inhibition of src and the mapk pathway overcomes intrinsic dasatinib resistance in cell lines where both the mapk and pi3k pathways are inhibited, which we show is likely due to the regulation of the pi3k pathway by src in these responsive cells. interestingly, we have mapped downstream phosphorylation of rps6 as a key biomarker of response, and cells that maintain rps6 phosphorylation likely represent drug tolerant persisters. altogether, the combined inhibition of src and the mapk pathway holds great promise for improving the overall survival of advanced thyroid cancer patients with braf and ras mutations, and activation of the pi3k pathway and rps6 phosphorylation represent important biomarkers of response for patients treated with this therapy.",pmc5833015,1,10,19,1,29
164,p70s6k,protein,constitutively active construct,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,rps6,protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,positive,d,phosphorylation,rps6,,,,human,['889'],nan,nan,"a previous report form axelrod et al.37, demonstrated that overexpression of a constitutively active p70s6k construct is able to overcome sensitivity to the combined inhibition of the her-family kinases and akt, through the maintenance of rps6 phosphorylation. surprisingly, we did not observe similar results with dasatinib and trametinib, which may be due to a difference in the mutational landscape of the cell lines tested, as the aforementioned study did not analyze cell lines with braf or ras mutations. in addition, rps6 is not the only node of convergence between the mapk and pi3k pathways, as additional effectors include the forkhead box o (foxo) family members, c-myc, bcl2-associated agonist of cell death (bad), gsk3, as well as others38. therefore, our data demonstrates that there may be alternative effectors mediating the oncogenic signaling outputs derived from the mapk and pi3k pathways, and that these alternative effectors should be analyzed in more detail to determine the key downstream nodes mediating growth and survival. interestingly in support of this, the majority of pik3ca-mutant thyroid cancer cell lines tested did not exhibit an increase in apoptosis in response to combined inhibition of src and the mapk pathway. furthermore, this is not completely surprising as our findings in fig. 1b uncovered an association between elevated levels of the pro-apoptotic proteins bax and smac being associated with src inhibitor sensitivity, suggesting that a link between src and pi3k pathway signaling can be uncoupled through the acquisition of pi3k mutations.",pmc5833015,1,10,18,1,28
